The estimated Net Worth of Sanket Shah is at least $12.1 Tisíc dollars as of 15 July 2023. Sanket Shah owns over 30,364 units of ViewRay stock worth over $9,657 and over the last few years Sanket sold VRAY stock worth over $2,429.
Sanket has made over 1 trades of the ViewRay stock since 2023, according to the Form 4 filled with the SEC. Most recently Sanket sold 30,364 units of VRAY stock worth $2,429 on 15 July 2023.
The largest trade Sanket's ever made was selling 30,364 units of ViewRay stock on 15 July 2023 worth over $2,429. On average, Sanket trades about 30,364 units every 0 days since 2023. As of 15 July 2023 Sanket still owns at least 386,295 units of ViewRay stock.
You can see the complete history of Sanket Shah stock trades at the bottom of the page.
Sanket's mailing address filed with the SEC is C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER, CO, 80202.
Over the last 8 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun a Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: